Last updated: May 26, 2026
Xifaxan is the branded form of rifaximin for GI indications. Supplier mapping hinges on (1) rifaximin API manufacture for tablet production and (2) third-party contract manufacturing of the finished-dose tablets under brand and label-control arrangements.
What follows is a supplier landscape at the level of generic pharmaceutical sourcing commonly used in commercial due diligence. It identifies the supplier types and how to verify the exact manufacturer for a given NDC/strength using regulatory label-control and FDA listing trails.
Which companies supply Xifaxan (rifaximin) tablets in the US?
Answer: Finished-dose Xifaxan supply is handled under the brand holder’s supply chain, typically via label-control and contract manufacturing. For due diligence, the authoritative supplier-by-NDC check is the FDA’s drug listing and label data tied to each NDC and strength.
Finished-dose supply chain: what to check
- NDC-to-label holder mapping
- Determine the NDC(s) for Xifaxan tablets by strength.
- Pull the associated labeler and manufacturer fields from FDA listings.
- Drug labeling and package insert manufacturer statements
- The labeling often lists the manufacturer and/or packager and may indicate where tablets are produced.
- Inspection and compliance signals
- FDA inspection history can indicate which sites actually manufacture the finished dosage form, not just distribute.
Who supplies rifaximin API used to make Xifaxan?
Answer: Rifaximin API for branded and generic rifaximin products is sourced from specialized API manufacturers that scale fermentation and purification chemistry. Exact API supplier(s) for a given Xifaxan batch are confirmed through FDA listing manufacturer fields for the dosage form and through NDA/CMC supply documentation, where available.
How API sourcing is verified in practice
- Regulatory field matching: match the finished-dose manufacturer site(s) that appear in FDA listings to upstream API supply contracts.
- Contract manufacturing footprints: identify CMO sites that repeatedly appear for rifaximin tablet products.
- Multi-source API reality: rifaximin API is frequently supplied from more than one qualified source to manage lead times and compliance.
What manufacturers produce rifaximin tablets (generic and branded) that may supply Xifaxan?
Answer: The US market for rifaximin tablets includes multiple manufacturers producing strengths commonly associated with GI indications. Xifaxan’s exact finished-dose plant and label-controlled product configuration are confirmed via FDA listing fields per NDC/strength.
Common verification workflow
- Cross-check each Xifaxan NDC strength against:
- FDA drug listing manufacturer/labeler fields
- Label package insert “Manufactured for/Distributed by” lines
- Any lot-specific “distributed by” / “manufactured by” statements on packaging
How many suppliers are typically in the Xifaxan supply chain (API and finished dose)?
Answer: Branded GI products usually operate with at least two qualified supplier paths: one for API and one for finished-dose manufacturing, with additional back-up sources for commercial continuity.
Supply chain structure
- API suppliers: typically multiple qualified sources globally to reduce dependency risk.
- Finished-dose manufacturers: one primary and one or more secondary sites, depending on volume, approvals, and inspection outcomes.
What are the biggest supplier concentration risks for Xifaxan (rifaximin)?
Answer: The highest risk points are plant-level compliance, API lead times, and batch release capacity at manufacturing sites.
Risk drivers
- Single-site finished-dose production: limits resilience to GMP interruptions.
- API bottlenecks: rifaximin API purification steps can constrain supply if a supplier has QC or regulatory issues.
- Regulatory inspection outcomes: delays can directly impact release timelines.
What does FDA listing data say about the Xifaxan manufacturer per NDC?
Answer: The FDA drug listing is the fastest public method to identify the labeler/manufacturer associated with each Xifaxan NDC strength.
What to extract from FDA listing per NDC
- NDC number
- labeler/holder
- manufacturer of record (site)
- dosage form and strength
How does Xifaxan compare with rifaximin generics in supplier structure?
Answer: Generics often expand supplier diversity due to multiple ANDA manufacturers. Xifaxan, as a branded product, typically has fewer qualified finished-dose sites but more controlled packaging and label governance.
Commercial implication
- Generics can reduce dependency risk through multi-site competition.
- Branded continuity depends on the brand holder’s procurement discipline and qualified back-up CMOs.
What about international suppliers for Xifaxan (rifaximin) outside the US?
Answer: Outside the US, Xifaxan is often produced and marketed under local licensing with site-specific CMOs. Supplier identities vary by country and can be verified through local regulator drug registers and local product labels.
International sourcing due diligence steps
- local drug register listing: manufacturer site and marketing authorization holder
- packaging label: manufacturer and packager statements
- local GMP compliance signals
Key Takeaways
- Xifaxan supplier mapping is best performed by NDC-strength verification using FDA listing fields, then tracing manufacturer sites to finished-dose production plants.
- Rifaximin API supply is handled by specialized API manufacturers; exact API suppliers for Xifaxan are typically confirmed through CMC documentation and label-control-to-site mapping rather than public marketing claims.
- Supplier concentration risks cluster at GMP plant capacity, API lead times, and batch release bottlenecks.
FAQs
-
How do I identify the Xifaxan manufacturer for a specific NDC/strength?
Use the FDA drug listing for that NDC strength to read the labeler/manufacturer-of-record fields.
-
Are there multiple qualified rifaximin API suppliers used for Xifaxan?
Branded product supply chains usually qualify more than one API source to maintain continuity, but the exact qualified set is confirmed through CMC supply documentation and batch release pathways.
-
Which contract manufacturers typically make rifaximin 200 mg tablets and 550 mg tablets?
Identify by NDC strength in FDA listings; rifaximin tablet production is often split across multiple tablet facilities across the market.
-
Does Xifaxan’s supplier list change after manufacturing site transfers?
Yes. Site changes commonly show up as updates in labeling and FDA listing manufacturer-of-record fields tied to NDC and lot release.
-
What data source best supports supply disruption scenario planning for Xifaxan?
FDA listing manufacturer site mapping plus GMP inspection and batch release history for the associated manufacturing facilities.
References (APA)
- US Food and Drug Administration. Drugs@FDA (drug product listing and labeling for NDC-linked manufacturer information). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (product and related references for branded vs generic rifaximin). https://www.accessdata.fda.gov/scripts/cder/ob/
